R
Robert D. Brook
Researcher at University of Michigan
Publications - 254
Citations - 16966
Robert D. Brook is an academic researcher from University of Michigan. The author has contributed to research in topics: Blood pressure & Population. The author has an hindex of 59, co-authored 254 publications receiving 13649 citations. Previous affiliations of Robert D. Brook include University of Maryland, Baltimore & University of Maryland, College Park.
Papers
More filters
Journal ArticleDOI
Long-term Air Pollution Exposure and Acceleration of Atherosclerosis and Vascular Inflammation in an Animal Model
Qinghua Sun,Aixia Wang,Ximei Jin,Alex Natanzon,Damon Duquaine,Robert D. Brook,Juan Gilberto S. Aguinaldo,Zahi A. Fayad,Valentin Fuster,Morton Lippmann,Lung Chi Chen,Sanjay Rajagopalan +11 more
TL;DR: In an apoE-/- mouse model, long-term exposure to low concentration of PM2.5 altered vasomotor tone, induced vascular inflammation, and potentiated atherosclerosis in a susceptible disease model.
Journal ArticleDOI
Air Pollution and Cardiovascular Disease: JACC State-of-the-Art Review
TL;DR: This review provides an overview of air pollution and health, including assessment of exposure, impact on CV outcomes, mechanistic underpinnings, and impact ofAir pollution reduction strategies to mitigate CV risk, and concludes with future challenges.
Journal ArticleDOI
Expert position paper on air pollution and cardiovascular disease
David E. Newby,Pier Mannuccio Mannucci,Grethe S. Tell,Andrea A. Baccarelli,Robert D. Brook,Ken Donaldson,Francesco Forastiere,Massimo Franchini,Oscar H. Franco,Ian D. Graham,Gerard Hoek,Barbara Hoffmann,Marc Hoylaerts,Nino Künzli,Nino Künzli,Nicholas L. Mills,Juha Pekkanen,Juha Pekkanen,Annette Peters,Massimo F Piepoli,Sanjay Rajagopalan,Robert F. Storey +21 more
TL;DR: An enduring positive association between long-term exposure to air pollution and total and cardiovascular mortality is established, mainly due to coronary artery disease.
Journal ArticleDOI
Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.
Robert M. Carey,David A. Calhoun,George L. Bakris,Robert D. Brook,Stacie L. Daugherty,Cheryl Dennison-Himmelfarb,Brent M. Egan,John M. Flack,Samuel S. Gidding,Eric Judd,Daniel T. Lackland,Cheryl L. Laffer,Christopher Newton-Cheh,Steven M. Smith,Sandra J. Taler,Stephen C. Textor,Tanya N. Turan,William B. White +17 more
TL;DR: Management of RH includes maximization of lifestyle interventions, use of long-acting thiazide-like diuretics, addition of a mineralocorticoid receptor antagonist (spironolactone or eplerenone), and, if BP remains elevated, stepwise addition of antihypertensive drugs with complementary mechanisms of action to lower BP.
Journal ArticleDOI
Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes
Brian A. Ference,Jennifer G. Robinson,Robert D. Brook,Alberico L. Catapano,M. John Chapman,David R. Neff,Szilard Voros,Robert P. Giugliano,George Davey Smith,Sergio Fazio,Marc S. Sabatine +10 more
TL;DR: In this paper, the effects of lower LDL cholesterol levels that were mediated by variants in PCSK9, HMGCR, or both on the risk of cardiovascular events and risk of diabetes were compared.